<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399215</url>
  </required_header>
  <id_info>
    <org_study_id>I 259114</org_study_id>
    <secondary_id>NCI-2015-00238</secondary_id>
    <secondary_id>I 259114</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT02399215</nct_id>
  </id_info>
  <brief_title>Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors</brief_title>
  <official_title>Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well nintedanib works in treating patients with
      neuroendocrine tumors that have spread from where they started to nearby tissue or lymph
      nodes (locally advanced) or have spread from the primary site (place where they started) to
      other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by
      slowing or stopping a certain type of receptor called vascular endothelial growth factor
      receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine
      tumors by blocking the growth of new blood vessels necessary for tumor growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess progression free survival (PFS), defined as the time interval from initiation of
      therapy, to its cessation for documentation of progressive disease (PD) or death.

      SECONDARY OBJECTIVES:

      I. To assess the clinical response (complete response + partial response) in all patients
      with measurable disease (using standard Response Evaluation Criteria in Solid Tumors [RECIST]
      version [v]1.1 criteria).

      II. To assess overall survival (OS) in all patients. III. Assess changes in quality of life
      (QOL) throughout treatment using the European Organization for Research and Treatment of
      Cancer (EORTC) quality of life questionnaire (QLQ) - Gastrointestinal Neuroendocrine Tumors
      (NET) 21 (GI.NET21) questionnaire for carcinoid patients with gastrointestinal neuroendocrine
      tumors, in all patients who have filled out at least two QOL questionnaires and, will be
      reported by groups based on response (response, stable disease or progressive disease).

      IV. Steady-state pharmacokinetics (PK) of nintedanib, biomarkers, regulatory T cell (Treg)
      and cytokine expression and growth factors will be analyzed for all patients and reported in
      groups based on response.

      V. Gene mutations and copy number alterations analysis in the mammalian target of rapamycin
      (mTOR) pathway (will be performed only on the first 10 patients), protein expression of
      activation of protein kinase B (Akt) (as well as other downstream targets).

      VI. Toxicity (graded using the National Cancer Institute [NCI] Common Terminology Criteria
      for Adverse Events [CTCAE] version 4.0) will be closely monitored and all toxicities will be
      tabulated.

      OUTLINE:

      Patients receive nintedanib orally (PO) twice daily (BID) on days 1-28. Courses repeat every
      28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Time interval from initiation of therapy, to its cessation for documentation of PD or death, assessed up to 2 years</time_frame>
    <description>Will be reported using standard Kaplan-Meier methods. Ninety-five percent confidence intervals for the median PFS will be calculated using Greenwood's formula. Additionally, a confidence interval for the 16-week PFS rate will be obtained using Jeffrey's prior method. The association between survival and quantified variables will be investigated using the Cox-proportional hazard model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QOL using the EORTC QLQ-GI.NET21 questionnaire</measure>
    <time_frame>Baseline to 30 days post-treatment</time_frame>
    <description>Will be analyzed in all patients who have filled out at least two QOL questionnaires and reported in three groups based on response (response, stable disease or progressive disease). An exact 90% confidence interval will be given for the rate of improved QOL. QOL will be analyzed using the logistic regression to investigate the association with quantified variables, such as biomarker expression and gene mutation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating marker levels (steady state PK, fibroblast growth factor [FGF] and fibroblast growth factor receptor [FGFR] and soluble vascular endothelial growth factor receptor 2 [sVEGFR2])</measure>
    <time_frame>Baseline</time_frame>
    <description>Dynamic contrast enhanced CT parameters will be reported and predictive value assessed using the PK/pharmacodynamics model previously developed by our group to explore association with PFS, clinical response, QOL and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response (complete response + partial response) measured using standard RECISTv1.1 criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Exact 90% confidence interval estimates using the Clopper-Pearson method will be given for the response rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median OS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be reported using standard Kaplan-Meier methods. Ninety-five percent confidence intervals for the median OS will be calculated using Greenwood's formula. The association between survival and quantified variables will be investigated using the Cox-proportional hazard model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of FGFR IIIb/IIIc and Ki-67 and microvessel density scores</measure>
    <time_frame>Baseline</time_frame>
    <description>Scores will be obtained to investigate association with PFS, clinical response, QOL and survival.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Will be analyzed for all patients and reported in groups based on response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cytokine expression</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Will be analyzed for all patients and reported in groups based on response. Changes in pre- and post-treatment cytokine expression will be analyzed using permutation paired t-tests.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in growth factors</measure>
    <time_frame>Baseline to 30 days post-treatment</time_frame>
    <description>Will be analyzed for all patients and reported in groups based on response. Changes in pre- and post-treatment growth factors will be analyzed using permutation paired t-tests.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene mutations and copy number alterations</measure>
    <time_frame>Baseline</time_frame>
    <description>Gene mutations and copy number alterations in the several pathways particularly mTOR pathway will be evaluated. Will be analyzed for all patients and correlated with clinical outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treg levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Will be analyzed for all patients and reported in groups based on response.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Carcinoid Tumor</condition>
  <condition>Metastatic Carcinoid Tumor</condition>
  <condition>Neuroendocrine Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (nintedanib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nintedanib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nintedanib)</arm_group_label>
    <other_name>BIBF 1120</other_name>
    <other_name>BIBF-1120</other_name>
    <other_name>Intedanib</other_name>
    <other_name>Multitargeted Tyrosine Kinase Inhibitor BIBF 1120</other_name>
    <other_name>tyrosine kinase inhibitor BIBF 1120</other_name>
    <other_name>Vargatef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nintedanib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (nintedanib)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be on a stable dose of octreotide (SandostatinÂ®) long-acting release
             (LAR) or lanreotide for 3 months prior to study enrollment

          -  Patient must have histologically or cytologically confirmed well differentiated or
             moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that
             is locally advanced or metastatic and not of pancreatic origin

          -  Measurable disease determined by computed tomography (CT) or magnetic resonance
             imaging (MRI)

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy greater than 3 months

          -  Leukocytes &gt;= 3,000/uL

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Total bilirubin =&lt; 2 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 1.5 x upper limit
             of normal (ULN) and bilirubin =&lt; ULN for patients without liver metastases

          -  AST/ALT =&lt; 2.5 x ULN and bilirubin =&lt; ULN for patients with liver metastases

          -  Patients with Gilbert syndrome and bilirubin &lt; 2 x ULN and normal AST/ALT

          -  Creatinine =&lt; 1.5 mg/dl

          -  Prior treatment will be permitted including surgery (&gt;= 4 weeks), cytotoxic
             chemotherapy (maximum of 2 prior regimens); radiation, interferon, targeted growth
             factors (&gt;= 4 weeks); and prior treatment with octreotide, will be allowed

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential (both male and female) must agree to use
             adequate contraceptive methods (e.g., hormonal or barrier method of birth control;
             abstinence) prior to study entry; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

          -  Archival tissue of carcinoid biopsy must be available

        Exclusion Criteria:

          -  Uncontrolled hypertension, unstable angina, New York Heart Association grade II or
             greater congestive heart failure, unstable symptomatic arrhythmia requiring
             medication, or clinically significant peripheral vascular disease (grade II or
             greater)

          -  Presence of brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 0, or anticipated need for major surgical procedure during the course of
             the study, or fine needle aspirations or core biopsies within 7 days prior to day 0

          -  Significant proteinuria at baseline (&gt;= 500 mg/24 hours [h])

          -  Serious non-healing wound, ulcer or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Recent (=&lt; 6 months) arterial thromboembolic events, including transient ischemic
             attack, cerebrovascular accident, unstable angina, or myocardial infarction

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma

          -  Hepatic artery embolization or ablation of hepatic metastasis within 3 months of
             enrollment, prior peptide receptor radionuclide therapy (PRRT) within 4 months or any
             other cancer therapy within 4 weeks (as long as all toxicities are resolved)

          -  Intolerance or hypersensitivity to octreotide

          -  Severe or uncontrolled medical conditions

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renuka Iyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

